Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5281136
Max Phase: Preclinical
Molecular Formula: C17H12BrFN2O
Molecular Weight: 359.20
Associated Items:
ID: ALA5281136
Max Phase: Preclinical
Molecular Formula: C17H12BrFN2O
Molecular Weight: 359.20
Associated Items:
Canonical SMILES: Cc1nc2ccc(Br)cc2c(=O)n1/C=C/c1ccc(F)cc1
Standard InChI: InChI=1S/C17H12BrFN2O/c1-11-20-16-7-4-13(18)10-15(16)17(22)21(11)9-8-12-2-5-14(19)6-3-12/h2-10H,1H3/b9-8+
Standard InChI Key: BQRZMMLPFCJDKE-CMDGGOBGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 359.20 | Molecular Weight (Monoisotopic): 358.0117 | AlogP: 4.23 | #Rotatable Bonds: 2 |
Polar Surface Area: 34.89 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 4.70 | CX LogP: 4.02 | CX LogD: 4.02 |
Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.69 | Np Likeness Score: -0.96 |
1. Alagarsamy V, Chitra K, Saravanan G, Solomon VR, Sulthana MT, Narendhar B.. (2018) An overview of quinazolines: Pharmacological significance and recent developments., 151 [PMID:29656203] [10.1016/j.ejmech.2018.03.076] |
Source(1):